NABI BIOPHARMACEUTICALS FILES LAWSUIT FOR INFRINGEMENT OF ITS PHOSLO(R) GELCAP PATENT

Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has filed a lawsuit against Roxane Laboratories, Inc. for infringement of its PhosLo(R) (calcium acetate) gelcap patent. The lawsuit was filed in the United States District Court for the Southern District of Ohio. The Company filed this lawsuit under the Hatch-Waxman Act in response to a Paragraph IV Certification letter submitted by Roxane to the Company concerning Roxane's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of the Company's PhosLo(R) (calcium acetate) GelCaps.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-27-2005/0004132661&EDATE=)